Malignant Neoplasms
GSK Initiates JPM Deal-making with $1 Billion Acquisition of IDRx for Rare Cancer Treatment
GSK, IDRx, JPM, rare cancer, acquisition, biotech, pharmaceuticals
Breakthroughs in Bladder Cancer Treatment: Protara and CG Oncology Report Encouraging Outcomes
Bladder Cancer Treatment, Protara Therapeutics, CG Oncology, TARA-002, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer (NMIBC), Oncolytic Immunotherapy, Cell Therapy
FDA Grants Accelerated Approval to Merus’ Bizengri for NRG1+ Lung and Pancreatic Cancers
Bizengri, NRG1+ cancers, FDA accelerated approval, lung cancer, pancreatic cancer, zenocutuzumab-zbco, Merus N.V.
Gilead Partners with Tubulis to Revitalize ADC Pipeline
Gilead Sciences, Tubulis, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Biotechnology Partnership
Takeda Acquires Rights to Rival BMS’ Reblozyl with $200M Upfront Payment to Keros
Takeda, Keros Therapeutics, Bristol-Myers Squibb, Reblozyl, Cancer Treatment, Pharmaceutical Deal
Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset
Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024
Merck and Kelun-Biotech Advance in Cancer Treatment with Exclusive License Agreement for Investigational ADC Candidates
Merck, Kelun-Biotech, Antibody-Drug Conjugates (ADC), Cancer Treatment, Exclusive License Agreement, TROP2, Nectin-4, SKB571
BeiGene Rebrands as BeOne Medicines, Emphasizing Global Unity Against Cancer
BeiGene, BeOne Medicines, Global Oncology, Cancer Treatment, Name Change, Strategic Growth
FDA Delays Decision on Merus’ Zenocutuzumab for NRG1+ Lung and Pancreatic Cancer
Zenocutuzumab, NRG1+ cancer, FDA delay, Merus, lung cancer, pancreatic cancer, bispecific antibody.
Crescent Biopharma’s Public Debut Fueled by PD-1/VEGF Combination Therapy Enthusiasm
PD-1/PD-L1 inhibitors, VEGF inhibitors, Combination therapy, Cancer treatment, Biopharmaceutical industry, Public listing